Personalized radiation therapy for head and neck cancer
Official title: Phase 2 Trial of Adaptive Radiotherapy Boost for Head and Neck Squamous Cell Carcinomas
Run by H. Lee Moffitt Cancer Center and Research Institute · NCT06137274 · Data updated 2026-11-12
This study is testing whether using MRI to tailor radiation therapy can improve treatment for people with head and neck cancer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 35 (estimated) |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Tampa, Florida) |
| Status | Recruiting |
| Started | December 14, 2023 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT06137274 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with confirmed squamous cell carcinoma of the head and neck who are willing to comply with study procedures.
✕Probably not a fit
Patients with non-squamous cell carcinoma or those who do not meet the eligibility criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the feasibility of using magnetic resonance imaging (MRI) to adapt radiation therapy for patients with head and neck squamous cell carcinoma. By personalizing treatment based on individual responses, the study seeks to optimize radiation delivery while adhering to standard care guidelines. The intervention involves intensity-modulated radiotherapy guided by MRI to enhance treatment effectiveness.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and tailored radiation treatments for patients with head and neck cancer.
How similar studies have gone: While the use of MRI in radiation therapy is an emerging field, similar adaptive approaches have shown promise in other cancer types, indicating potential for success in this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * ECOG performance status of 0, 1 * Patients with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or unknown primary in the neck. * Patients with measurable disease, either at primary site or neck per RECIST 1.1. * For patients planned to receive chemotherapy, adequate hematologic, hepatic and renal function as outlined in protocol. * International normalized ratio of prothrombin time (INR) and prothrombin time (PT) within 28 days before randomization must be WNL for the lab. Patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history. * Negative serum pregnancy test within before starting study treatment in woman with childbearing potential. Exclusion Criteria: * Pregnancy or lactation * Patients who have had prior radiotherapy to the head and neck or prior systemic therapy for the index cancer. * Patients who had undergone definitive surgery for the index cancer. * Patients with distant metastatic disease * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
Where it's running
-
Moffitt Cancer Center
Tampa, Florida, United States Recruiting
Study contacts
- Principal investigator: George Yang, MD — Moffitt Cancer Center
- Study coordinator: Ashley Brennaman
- Email: ashley.brennaman@moffitt.org
- Phone: 813-745-5467
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Targeted dual-imaging helper for head and neck cancer surgery
This study tests whether using two imaging agents during surgery can help doctors see tumors and cancerous lymph nodes in adults with head and neck squamous cell carcinoma.
-
Induction therapy with toripalimab plus cisplatin and docetaxel for head and neck squamous cell carcinoma
This study tests whether adding toripalimab to cisplatin and docetaxel induction therapy is safe and tolerable for adults with newly diagnosed locally advanced head and neck squamous cell carcinoma.
-
Neoadjuvant chemoimmunotherapy with PD-1 blockade to reduce surgery for advanced head and neck cancer
This approach will try a short course of chemotherapy plus the PD-1 drug toripalimab before standard treatment for people with advanced head and neck cancers to shrink tumors and allow less extensive surgery or radiation.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Airway ultrasound in head and neck cancer patients
This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.